Aminoglycoside-induced mutation suppression (stop codon readthrough) as a therapeutic strategy for Duchenne muscular dystrophy

Therapeutic Advances in Neurological Disorders

Volumn 3, Issue 6, 2010, Pages 379-389

  Malik, Vinod ^a   Rodino Klapac, Louise R ^a   Viollet, Laurence ^a   Mendell, Jerry R ^a  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

DMD; dystrophinopathy; gentamicin; mutation suppression; readthrough

Indexed keywords

AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; ANTIBIOTIC G 418; ATALUREN; CREATINE KINASE; CYSTATIN C; DYSTROPHIN; GAMMA INTERFERON; GENTAMICIN; NB 54; NB 74; NB 84; NEGAMYCIN; POLYASPARTIC ACID; TOBRAMYCIN; TRANSMEMBRANE CONDUCTANCE REGULATOR; UNCLASSIFIED DRUG;

CELLULAR IMMUNITY; CLINICAL TRIAL; CYTOKINE RESPONSE; CYTOTOXICITY; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DUCHENNE MUSCULAR DYSTROPHY; HIGH THROUGHPUT SCREENING; HUMAN; INDUCED MUTATION; NONHUMAN; NONSENSE MEDIATED MRNA DECAY; NONSENSE MUTATION; OTOTOXICITY; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REVIEW; STOP CODON; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

EID: 78649914981     PISSN: 17562856     EISSN: None     Source Type: Journal    
DOI: 10.1177/1756285610388693     Document Type: Review

References (62)

1. Ahmad, A., Brinson, M., Hodges, B.L., Chamberlain, J.S. and Amalfitano, A. ( 2000) Mdx mice inducibly expressing dystrophin provide insights into the potential of gene therapy for Duchenne muscular dystrophy. Hum Mol Genet 9: 2507-2515.
2. Anderson, W.F., Gorini, L. and Breckenridge, L. ( 1965) Role of ribosomes in streptomycin-activated suppression. Proc Natl Acad Sci U S A 54: 1076-1083.
3. Arakawa, M., Shiozuka, M., Nakayama, Y., Hara, T., Hamada, M., Kondo, S. et al. (2003) Negamycin restores dystrophin expression in skeletal and cardiac muscles of mdx mice. J Biochem 134: 751-758.
4. Barton-Davis, E.R., Cordier, L., Shoturma, D.I., Leland, S.E. and Sweeney, H.L. ( 1999) Aminoglycoside antibiotics restore dystrophin function to skeletal muscles of mdx mice. J Clin Invest 104: 375-381.
5. Bedwell, D.M., Kaenjak, A., Benos, D.J., Bebok, Z., Bubien, J.K., Hong, J. et al. (1997) Suppression of a CFTR premature stop mutation in a bronchial epithelial cell line. Nat Med 3: 1280-1284.
6. Bidou, L., Hatin, I., Perez, N., Allamand, V., Panthier, J.J. and Rousset, J.P. ( 2004) Premature stop codons involved in muscular dystrophies show a broad spectrum of readthrough efficiencies in response to gentamicin treatment. Gene Ther 11: 619-627.
7. Biggar, W.D., Harris, V.A., Eliasoph, L. and Alman, B. ( 2006) Long-term benefits of deflazacort treatment for boys with Duchenne muscular dystrophy in their second decade. Neuromuscul Disord 16: 249-255.
8. Burke, J.F. and Mogg, A.E. ( 1985) Suppression of a nonsense mutation in mammalian cells in vivo by the aminoglycoside antibiotics G-418 and paromomycin. Nucleic Acids Res 13: 6265-6272.
9. Bushby, K., Finkel, R., Birnkrant, D.J., Case, L.E., Clemens, P.R., Cripe, L. et al. (2010) Diagnosis and management of Duchenne muscular dystrophy, part 1: diagnosis, and pharmacological and psychosocial management. Lancet Neurol 9: 77-93.
10. Campbell, K.P. and Kahl, S.D. ( 1989) Association of dystrophin and an integral membrane glycoprotein. Nature 338: 259-262.
11. Davies, J., Gilbert, W. and Gorini, L. ( 1964) Streptomycin, suppression, and the code. Proc Natl Acad Sci U S A 51: 883-890.
12. de Luca, A., Nico, B., Rolland, J.F., Cozzoli, A., Burdi, R., Mangieri, D. et al. (2008) Gentamicin treatment in exercised mdx mice: Identification of dystrophin-sensitive pathways and evaluation of efficacy in work-loaded dystrophic muscle. Neurobiol Dis 32: 243-253.
13. Dent, K.M., Dunn, D.M., von Niederhausern, A.C., Aoyagi, A.T., Kerr, L., Bromberg, M.B. et al. (2005) Improved molecular diagnosis of dystrophinopathies in an unselected clinical cohort. Am J Med Genet A 134: 295-298.
14. Du, L., Damoiseaux, R., Nahas, S., Gao, K., Hu, H., Pollard, J.M. et al. (2009 a) Nonaminoglycoside compounds induce readthrough of nonsense mutations. J Exp Med 206: 2285-2297.
15. Du, M., Jones, J.R., Lanier, J., Keeling, K.M., Lindsey, J.R., Tousson, A. et al. (2002) Aminoglycoside suppression of a premature stop mutation in a Cftr-/- mouse carrying a human CFTRG542X transgene. J Mol Med 80: 595-604.
16. Du, M., Keeling, K.M., Fan, L., Liu, X. and Bedwell, D.M. (2009 b) Poly-L-aspartic acid enhances and prolongs gentamicin-mediated suppression of the CFTR-G542X mutation in a cystic fibrosis mouse model. J Biol Chem 284: 6885-6892.
17. Du, M., Keeling, K.M., Fan, L., Liu, X., Kovacs, T., Sorscher, E. et al. (2006) Clinical doses of amikacin provide more effective suppression of the human CFTR-G542X stop mutation than gentamicin in a transgenic CF mouse model. J Mol Med 84: 573-582.
18. Dunant, P., Walter, M.C., Karpati, G. and Lochmuller, H. ( 2003) Gentamicin fails to increase dystrophin expression in dystrophin-deficient muscle. Muscle Nerve 27: 624-627.
19. Ervasti, J.M., Ohlendieck, K., Kahl, S.D., Gaver, M.G. and Campbell, K.P. ( 1990) Deficiency of a glycoprotein component of the dystrophin complex in dystrophic muscle. Nature 345: 315-319.
20. Fan-Minogue, H. and Bedwell, D.M. ( 2008) Eukaryotic ribosomal RNA determinants of aminoglycoside resistance and their role in translational fidelity. RNA 14: 148-157.
21. Flanigan, K.M., von Niederhausern, A., Dunn, D.M., Alder, J., Mendell, J.R. and Weiss, R.B. (2003) Rapid direct sequence analysis of the dystrophin gene. Am J Hum Genet 72: 931-939.
22. Fourmy, D., Recht, M.I., Blanchard, S.C. and Puglisi, J.D. ( 1996) Structure of the A site of Escherichia coli 16S ribosomal RNA complexed with an aminoglycoside antibiotic. Science 274: 1367-1371.
23. Gardner-Medwin, D. ( 1970) Mutation rate in Duchenne type of muscular dystrophy. J Med Genet 7: 334-337.
24. Ghahramani Seno, M.M., Graham, I.R., Athanasopoulos, T., Trollet, C., Pohlschmidt, M., Crompton, M.R. et al. (2008) RNAi-mediated knockdown of dystrophin expression in adult mice does not lead to overt muscular dystrophy pathology. Hum Mol Genet 17: 2622-2632.
25. Hamed, S.A. ( 2006) Drug evaluation: PTC-124-a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 9: 783-789.
26. Harper, S.Q., Hauser, M.A., DelloRusso, C., Duan, D., Crawford, R.W., Phelps, S.F. et al. (2002) Modular flexibility of dystrophin: implications for gene therapy of Duchenne muscular dystrophy. Nat Med 8: 253-261.
27. Harmann, T. ( 2007) Aminoglycoside antibiotics: Old drugs and new therapeutic approaches. Cell Mol Life Sci 64: 1841-1852.
28. Hirawat, S., Welch, E.M., Elfring, G.L., Northcutt, V.J., Paushkin, S., Hwang, S. et al. (2007) Safety, tolerability, and pharmacokinetics of PTC124, a nonaminoglycoside nonsense mutation suppressor, following single- and multiple-dose administration to healthy male and female adult volunteers. J Clin Pharmacol 47: 430-444.
29. Hoffman, E.P., Brown Jr, R.H. and Kunkel, L.M. ( 1987) Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 51: 919-928.
30. Howard, M., Frizzell, R.A. and Bedwell, D.M. ( 1996) Aminoglycoside antibiotics restore CFTR function by overcoming premature stop mutations. Nat Med 2: 467-469.
31. Howard, M.T., Shirts, B.H., Petros, L.M., Flanigan, K.M., Gesteland, R.F. and Atkins, J.F. ( 2000) Sequence specificity of aminoglycoside-induced stop codon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann Neurol 48: 164-169.
32. Kerem, E., Hirawat, S., Armoni, S., Yaakov, Y., Shoseyov, D., Cohen, M. et al. (2008) Effectiveness of PTC 124 treatment of cystic fibrosis caused by nonsense mutations: a prospective phase II trial. Lancet 372: 719-727.
33. Kimura, S., Ito, K., Miyagi, T., Hiranuma, T., Yoshioka, K., Ozasa, S. et al. (2005) A novel approach to identify Duchenne muscular dystrophy patients for aminoglycoside antibiotics therapy. Brain Dev 27: 400-405.
34. King, W.M., Ruttencutter, R., Nagaraja, H.N., Matkovic, V., Landoll, J., Hoyle, C. et al. (2007) Orthopedic outcomes of long-term daily corticosteroid treatment in Duchenne muscular dystrophy. Neurology 68: 1607-1613.
35. Koenig, M., Hoffman, E.P., Bertelson, C.J., Monaco, A.P., Feener, C. and Kunkel, L.M. ( 1987) Complete cloning of the Duchenne muscular dystrophy (DMD) cDNA and preliminary genomic organization of the DMD gene in normal and affected individuals. Cell 50: 509-517.
36. Koenig, M., Monaco, A.P. and Kunkel, L.M. ( 1988) The complete sequence of dystrophin predicts a rod-shaped cytoskeletal protein. Cell 53: 219-228.
37. Linde, L., Boelz, S., Nissim-Rafinia, M., Oren, Y.S., Wilschanski, M., Yaacov, Y. et al. (2007) Nonsense-mediated mRNA decay affects nonsense transcript levels and governs response of cystic fibrosis patients to gentamicin. J Clin Invest 117: 683-692.
38. Loufrani, L., Dubroca, C., You, D., Li, Z., Levy, B., Paulin, D. et al. (2004) Absence of dystrophin in mice reduces NO-dependent vascular function and vascular density: total recovery after a treatment with the aminoglycoside gentamicin. Arterioscler Thromb Vasc Biol 24: 671-676.
39. Loveless, M.O., Kohlhepp, S.J. and Gilbert, D.N. ( 1984) The influence of aminoglycoside antibiotics on the in vitro function of rat liver ribosomes. J Lab Clin Med 103: 294-303.
40. Malik, V., Rodino-Klapac, L.R., Viollet, L., Wall, C., King, W., Al-Dahhak, R. et al. (2010) Gentamicin-induced readthrough of stop codons in Duchenne muscular dystrophy. Ann Neurol 67: 771-780.
41. Manuvakhova, M., Keeling, K. and Bedwell, D.M. ( 2000) Aminoglycoside antibiotics mediate context-dependent suppression of termination codons in a mammalian translation system. RNA 6: 1044-1055.
42. Martin, R., Mogg, A.E., Heywood, L.A., Nitschke, L. and Burke, J.F. ( 1989) Aminoglycoside suppression at UAG, UAA and UGA codons in Escherichia coli and human tissue culture cells. Mol Gen Genet 217: 411-418.
43. Mendell, J.R., Buzin, C.H., Feng, J., Yan, J., Serrano, C., Sangani, D.S. et al. (2001) Diagnosis of Duchenne dystrophy by enhanced detection of small mutations. Neurology 57: 645-650.
44. Mendell, J.R., Engel, W.K. and Derrer, E.C. ( 1971) Duchenne muscular dystrophy: functional ischemia reproduces its characteristic lesions. Science 172: 1143-1145.
45. Mendell, J.R., Moxley, R.T., Griggs, R.C., Brooke, M.H., Fenichel, G.M., Miller, J.P. et al. (1989) Randomized, double-blind six-month trial of prednisone in Duchenne's muscular dystrophy. N Engl J Med 320: 1592-1597.
46. Mendell, J.R., Campbell, K., Rodino-Klapac, L., Sahenk, Z., Shilling, C., Lewis, L. et al. (2010) Dystrophin immunity in Duchenne muscular dystrophy. N Eng J Med 363: 1429-1437.
47. Nagy, E. and Maquat, L.E. ( 1998) A rule for termination-codon position within intron-containing genes: when nonsense affects RNA abundance. Trends Biochem Sci 23: 198-199.
48. Neri, M., Torelli, S., Brown, S., Ugo, I., Sabatelli, P., Merlini, L. et al. (2007) Dystrophin levels as low as 30% are sufficient to avoid muscular dystrophy in the human. Neuromuscul Disord 17: 913-918.
49. Nudelman, I., Glikin, D., Smolkin, B., Hainrichson, M., Belakhov, V. and Baasov, T. (2010) Repairing faulty genes by aminoglycosides: development of new derivatives of geneticin (G418) with enhanced suppression of diseases-causing nonsense mutations. Bioorg Med Chem 18: 3735-3746.
50. Nudelman, I., Rebibo-Sabbah, A., Cherniavsky, M., Belakhov, V., Hainrichson, M., Chen, F. et al. (2009) Development of novel aminoglycoside (NB54) with reduced toxicity and enhanced suppression of disease-causing premature stop mutations. J Med Chem 52: 2836-2845.
51. Politano, L., Nigro, G., Nigro, V., Piluso, G., Papparella, S., Paciello, O. et al. (2003) Gentamicin administration in Duchenne patients with premature stop codon. Preliminary results. Acta Myol 22: 15-21.
52. Sander, M., Chavoshan, B., Harris, S.A., Iannaccone, S.T., Stull, J.T., Thomas, G.D. et al. (2000) Functional muscle ischemia in neuronal nitric oxide synthasedeficient skeletal muscle of children with Duchenne muscular dystrophy. Proc Natl Acad Sci U S A 97: 13818-13823.
53. Stephens, F.E. and Tyler, F.H. ( 1951) Studies in disorders of muscle. V. The inheritance of childhood progressive muscular dystrophy in 33 kindreds. Am J Hum Genet 3: 111-125.
54. Stevenson, A.C. ( 1958) Muscular dystrophy in Northern Ireland. IV. Some additional data. Ann Hum Genet 22: 231-234.
55. Tang, H.Y., Hutcheson, E., Neill, S., Drummond-Borg, M., Speer, M. and Alford, R.L. ( 2002) Genetic susceptibility to aminoglycoside ototoxicity: how many are at risk? Genet Med 4: 336-345.
56. Viollet, L., Gailey, S., Thornton, D.J., Friedman, N.R., Flanigan, K.M., Mahan, J.D. et al. (2009) Utility of cystatin C to monitor renal function in Duchenne muscular dystrophy. Muscle Nerve 40: 438-442.
57. Wagner, K.R., Hamed, S., Hadley, D.W., Gropman, A.L., Burstein, A.H., Escolar, D.M. et al. (2001) Gentamicin treatment of Duchenne and Becker muscular dystrophy due to nonsense mutations. Ann Neurol 49: 706-711.
58. Walton, J.N., Race, R.R. and Philip, U. ( 1955) On the inheritance of muscular dystrophy; with a note on the blood groups, and a note on colour vision and linkage studies. Ann Hum Genet 20: 1-38.
59. Wilton, S.D., Lloyd, F., Carville, K., Fletcher, S., Honeyman, K., Agrawal, S. et al. (1999) Specific removal of the nonsense mutation from the mdx dystrophin mRNA using antisense oligonucleotides. Neuromuscul Disord 9: 330-338.
60. Worton, R.G. ( 1992) Duchenne muscular dystrophy: gene and gene product; mechanism of mutation in the gene. J Inherit Metab Dis 15: 539-550.
61. Yoshida, M. and Ozawa, E. ( 1990) Glycoprotein complex anchoring dystrophin to sarcolemma. J Biochem 108: 748-752.
62. Yoshizawa, S., Fourmy, D. and Puglisi, J.D. ( 1998) Structural origins of gentamicin antibiotic action. EMBO J 17: 6437-6448.